Side-by-side · Research reference
DihexavsPancragen
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-StrongHUMAN-REVIEWED7/28 cited
BAnimal-StrongHUMAN-REVIEWED23/39 cited
Dihexa
Angiotensin IV Analogue · Pre-Clinical
Not established — animal studies only
01Mechanism of Action
Parameter
Dihexa
Pancragen
Primary target
c-Met receptor (HGF receptor tyrosine kinase)
Pancreatic acinar and islet cell differentiation pathwaysKhavinson 2013
Pathway
HGF/c-Met receptor activation → downstream signaling cascade → synaptogenesis and dendritic arborization
Transcription factor activation → Pdx1/Pax6/Pax4/Ptf1a/Foxa2/NKx2.2 upregulation → Cell differentiationKhavinson 2013
Downstream effect
Induction of dendritic arborization, synapse formation, neurogenesis, and neuroprotection in rodent models
Enhanced pancreatic beta-cell function, normalized insulin/C-peptide dynamics, improved glucose clearanceGoncharova 2014
Feedback intact?
—
Yes — preserves physiological glucose-insulin response
Origin
Small-molecule angiotensin IV analogue designed to activate HGF/c-Met systemWright 2015
Synthetic tetrapeptide derived from pancreatic tissue extracts (Khavinson bioregulator methodology)
Antibody development
—
—
02Dosage Protocols
Parameter
Dihexa
Pancragen
Human dosing
Not established — no human trials
—
Animal studies
Mouse/rat models only — dosing not translatable to humans
—
Evidence basis
Pre-clinical / Rodent models
Non-human primate RCT, in vitro cell cultureGoncharova 2015Khavinson 2013
Clinical status
No Phase 1, 2, or 3 trials published
—
Primate dose (rhesus macaque)
—
50 μg / animal / dayGoncharova 2014
20–25-year-old females, 10-day IM protocol.
Effective concentration (in vitro)
—
0.05 ng/mLZakutskiĭ 2006
Organotypic tissue culture, both young and aged rat explants.
Diabetes model
—
STZ-induced diabetes (rat)
Evaluated via metabolic markers characterizing apoptosis.
04Side Effects & Safety
Parameter
Dihexa
Pancragen
Human safety data
None available — no human clinical trials
No published human trials; clinical use limited to Russian gerontology protocols
Theoretical c-Met risks
c-Met receptor activation has been implicated in tumorigenesis; unknown cancer risk profile
—
Pre-clinical tolerability
Not systematically reported in available studies
—
Reported adverse events
—
None documented in primate studies
Absolute Contraindications
Dihexa
- ·Not approved for human use — research compound only
Pancragen
—Relative Contraindications
Dihexa
- ·Theoretical contraindication: active or history of malignancy (c-Met pathway involvement in cancer)
Pancragen
- ·Active pancreatic malignancy (proliferation marker upregulation)
05Administration Protocol
Parameter
Dihexa
Pancragen
1. Human administration
No established protocol. Dihexa has not been tested in human subjects. Animal studies used various routes (typically subcutaneous or intraperitoneal in rodents) not translatable to clinical use.
Lyophilised tetrapeptide reconstituted in sterile saline or water per manufacturer protocol. Concentration not specified in literature.
2. Legal status
Pre-clinical research compound. Not approved by FDA or any regulatory authority for human use.
Intramuscular injection. Primate studies used daily IM dosing for 10 consecutive days.Goncharova 2015
3. Timing
—
No specific timing constraints documented. Administered once daily in primate protocols.
4. Cycle structure
—
10-day treatment course. Restorative effects on pancreatic function persist for at least 3 weeks post-discontinuation.Goncharova 2014